Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
The planned study will analyze more than 60,000 serum samples alongside real-world clinical data.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alamar Biosciences (ALMR) announced a scientific collaboration with GSK to study circulating proteins across multiple disease areas using its NULISA platform. The study will analyze more than 60,000 serum samples from a diverse patient cohort using the NULISAseq Immune 340 and Neuro 220 panels.
The companies aim to combine protein measurements with real-world clinical data to identify biological subtypes and examine disease progression and treatment response. The work covers respiratory, liver, kidney, neurological and autoimmune conditions, with the goal of informing earlier detection and precision treatment.
Positive
- Minor point. Forward-looking: it has not happened yet and may not happen.GSK scientific collaboration will use Alamar’s NULISA platform to analyze more than 60,000 serum samples.
Negative
- None.
Key Figures
- Serum samples
- More than 60,000 samples
- GSK collaboration; NULISAseq Immune 340 and NULISAseq Neuro 220 panels
Key Terms
proteomic technical
biomarker medical
endotyping medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Alamar’s NULISAseq™ Immune 340 and NULISAseq™ Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment response
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc (LSE/NYSE: GSK) that will use Alamar’s NULISA™ platform in a large-scale study examining how circulating protein signatures relate to disease progression, biological subtypes and treatment response across respiratory, liver, kidney, neurological and autoimmune conditions. The collaboration intends to generate deep proteomic insights to advance precision prevention, treatment and earlier disease detection in real-world health care settings.
Many diseases that share the same clinical diagnosis encompass biologically distinct patient populations, contributing to differences in disease progression and treatment response. By combining large-scale proteomic profiling with real-world clinical data, Alamar and GSK aim to identify protein signatures that better distinguish these underlying biological differences and improve how disease is classified, studied and treated.
To achieve these goals, Alamar’s NULISA platform will analyze more than 60,000 serum samples, drawn from a diverse patient cohort, using the NULISAseq Immune 340 and NULISAseq Neuro 220 panels. The combination of immune and neurological proteomic profiling at this scale is designed to generate a deep biomarker dataset spanning disease areas where heterogeneity has historically made therapeutic development difficult.
The scientific collaboration will focus on the following areas of inquiry:
- Proteomic correlates of disease outcomes: mapping protein signals to recorded diagnoses, prescribing patterns, and clinical events
- Diagnostic, prognostic, and predictive biomarker identification: characterizing single and multiplex protein patterns associated with disease susceptibility and severity over time and throughout aging
- Mechanistic endotyping: uncovering the biological subtypes underlying conditions currently grouped under a single clinical label
- Proteomic measures of drug response: characterizing how patients’ protein profiles relate to individualized responses to existing therapeutic mechanisms
“Proteomics has emerged as one of the most promising frontiers in precision medicine, and the quality of measurements from Alamar's NULISA platform offer enormous potential,” said Robert Scott, senior vice president, R&D translational sciences at GSK. “By profiling the proteome at scale across a diverse patient population, we have the potential to shape how we identify patient populations, design clinical trials, and ultimately develop more targeted and effective therapies. This collaboration offers considerable promise to advance our work to discover and develop medicines for patients.”
“We believe the application of our ultra-sensitive NULISA platform will uncover proteomic patterns that were previously obscured, yielding signatures capable of stratifying patients for precision prevention and treatment at the earliest possible stage,” said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “The insights generated here have the potential inform drug development programs and advance a new standard for what proteomics can deliver in precision medicine.”
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
About Alamar Biosciences
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com.
Forward Looking Statements
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar’s NULISA platform’s ability to uncover previously obscured proteomic patterns and yield signatures capable of stratifying patients for precision prevention and treatment at the earliest possible stage. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on August 11, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Media Contact:
Media@alamarbio.com
Investor Contact:
Investors@alamarbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Alamar Biosciences and GSK study in their proteomics collaboration?
Alamar and GSK will examine how circulating protein signatures relate to disease progression, biological subtypes and treatment response. The study will use Alamar’s NULISA platform to analyze more than 60,000 serum samples across respiratory, liver, kidney, neurological and autoimmune conditions.
How will the Alamar-GSK study investigate protein signals and disease outcomes?
The study will map protein signals to recorded diagnoses, prescribing patterns and clinical events. It will also characterize protein patterns associated with disease susceptibility and severity over time and throughout aging, investigate biological subtypes within shared diagnoses, and examine protein profiles associated with individualized drug responses.